334 results about "Dementia" patented technology

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

The embodiment of the invention relates to a processing method and device of an Alzheimer disease risk prediction model. The method comprises the steps that DT I-ALPS feature information of dementia crowds and healthy crowds of a specified age group is obtained in a big data collection and volunteer recruitment mode, and a corresponding model data set is constructed and recorded as a first data set; constructing a three-classification prediction model for predicting the risk of the Alzheimer's disease as an Alzheimer's disease risk prediction model corresponding to a specified age group; training an Alzheimer disease risk prediction model based on the first data set; after model training is finished, DT I-ALPS feature information, input by the user, of any tested person of the specified age group is input into the Alzheimer disease risk prediction model for prediction, and a corresponding classification probability vector is obtained and fed back to the current user. According to the invention, prediction accuracy and prediction stability can be improved.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

The invention discloses a dementia identification method based on brain computer network space cross attention fusion. The dementia identification method comprises the steps that resting-state electroencephalogram signals are acquired, preprocessing and brain network construction are carried out, the frequency band power ratio is calculated, and a training set and a test set are divided; the brain network fuses the spatial information, and spatial features are obtained through an isotropic graph neural network and a local feature enhancement module; the frequency band power ratio is coded by a multi-layer perceptron to obtain frequency spectrum statistical characteristics; a bidirectional cross attention module is input, and complementary fusion features are extracted; and performing mixed pooling and splicing on the complementary fusion features, then sending the fused features to a Chebyshev Kolmogorov-Arnold network classifier, and outputting an Alzheimer's disease / frontotemporal dementia / health control (AD / FTD / HC) classification result and a cognitive scale evaluation score (MMSE). According to the method, the multi-feature complementary information is effectively integrated through joint modeling of the spatial diagram features and the global spectrum features, and the accuracy, stability and generalization ability of AD and FTD classification in a complex brain network are improved.

The invention discloses a dementia intervention scheme recommendation method and system based on a knowledge graph, and relates to the technical field of intelligent medical treatment and artificial intelligence. And constructing a dementia intervention knowledge graph containing patients, symptoms, intervention measures and environmental elements. And performing intelligent semantic reasoning on the short-term state, the long-term behavior mode and the nursing environment of the patient by fusing multi-level reasoning and situational reasoning, generating a candidate intervention scheme matched with the current state of the patient, and outputting a personalized recommendation result. In the intervention implementation process, the knowledge graph association relation is dynamically updated based on patient behavior feedback and symptom changes, and continuous optimization and self-adaptive adjustment of an intervention scheme are achieved. According to the method, the individuation level, long-term adaptability and safety of dementia intervention recommendation are improved, and the method is suitable for clinical and long-term nursing scenes.

Provided is a data processing system capable of detecting that a user may have initial symptoms of dementia.　The data processing system comprises: a necklace-type terminal including a microphone that collects a user utterance of a wearer, a collection unit that collects an output of the microphone, and a communication unit that transmits the output of the microphone collected by the collection unit to an external device; and a data processing device. The data processing device includes: an input unit that receives the user utterance collected by the microphone; and a processing unit that, when a remark indicating a sign of dementia is included in the user utterance, notifies a preset notification destination that the wearer may have dementia.

Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a microtubule associated protein tau (MAPT) gene. The MAPT RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of a MAPT gene. The MAPT RNAi agents are conjugated to an antigen binding protein that may enable subcutaneous delivery of the RNAi agents by facilitating crossing of the blood brain barrier (BBB). Pharmaceutical compositions that include one or more MAPT RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described MAPT RNAi agents to central nervous system (CNS) tissue, in vivo, provides for inhibition of MAPT gene expression and a reduction in MAPT activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including Alzheimer's disease, Frontotemporal lobar degeneration dementia (FTLD), Progressive supranuclear palsy, and other tauopathies.

The invention discloses a daily life activity ability assessment method and system based on a multi-branch space-time fusion network. The method comprises the steps of collecting motion data of a to-be-evaluated object, performing segmentation, noise reduction and standardization preprocessing, and extracting time-frequency domain features and motion deviation degree, motion similarity index and bilateral symmetry index provided by the invention; obtaining a uniform Bhattacharyya index scale score; and taking the motion feature data set and the clinical score as input, performing training based on a multi-branch space-time fusion algorithm, constructing a multi-task prediction model, and realizing automatic evaluation of the ADL. According to the method, the multi-branch space-time fusion network is innovatively introduced, the relevance between tasks is fully utilized, the spatial feature extraction capability is enhanced in combination with the graph neural network, adaptive fusion of the features is realized through a cross-layer interactive attention mechanism, the model prediction precision and evaluation reliability are remarkably improved, and the method is suitable for large-scale popularization and application. And an effective technical support is provided for rehabilitation evaluation and personalized treatment of patients with dyskinesia and disability and dementia.

An analytics computing device is provided. The analytics computing device includes a processor in communication with a database. The database configured to store electronic health record (EHR) data including structured EHR data and unstructured EHR data for a patient. The processor is configured to retrieve the EHR data from the database. The processor is further configured to parse, using a natural language processing model, the unstructured EHR data to retrieve one or more indicator phrases, the one or more indicator phrases correlated to an Alzheimer's disease (AD) diagnosis. The processor is further configured to identify, using a predictive model, the patient as being at risk for AD based on the retrieved indicator phrases and on the structured EHR data.

In the homes where elderly people are accustomed to living, the knee joints are subjected to a lot of stress when going up and down stairs, especially when going down them, which causes frequent falls and can lead to serious health problems such as fractures, hospitalization, and even becoming bedridden or experiencing the progression of dementia. [Solution] Hydraulic bags containing hydraulic oil are placed under the treads of each staircase, and the hydraulic bags are connected to each other by hoses with control valves. When the operating lever inside the handrail is gripped, the wire opens the control valve, and the hydraulic oil is pushed out by the user's weight, causing the treads to descend. The pushed-out hydraulic oil is injected into an empty hydraulic bag container on the floor below, causing the treads on the lower floor to rise and be at the same floor height. This provides an inexpensive, non-powered elevator "specialized for descending," allowing users to easily descend to the floor below without bending their knees.

To provide an AI system capable of estimating severity of dementia and / or depression in a subject on the basis of information obtained outside a hospital.SOLUTION: A method of creating teacher data for an AI system for estimating severity of dementia and / or depression is provided. Information to be used as teacher data for the AI system can be acquired from a site where a user receives prescribed drugs or from an application on a mobile terminal used by the user. The teacher data at least includes a face picture of the user, and a prescription, instruction, or information that enables estimation of dementia and / or depression in the user.SELECTED DRAWING: Figure 1

The present invention relates to a system and method configured for analysing acoustic parameters of speech to detect, diagnose, predict and / or monitor progression of a condition, disorder, or disease, and more particularly, any of paediatric and adult neurological and central nervous system conditions including but not limited to low back pain, multiple sclerosis, stroke, seizures, Alzheimer's disease, Parkinson's disease, dementia, motor neuron disease, muscular atrophy, acquired brain injury, cancers involving neurological deficits, paediatric developmental conditions and rare genetic disorders such as spinal muscular atrophy. The system and method extracts a first formant data set from words spoken by an individual and uses these to classify the vowels in the words on a first computing device, such as a mobile smart phone equipped with a microphone into which an individual speaks. The system stores at least some of these frequencies for the vowel formants in a second formant data set as a recorded file and provides the second formant data set as input to acoustic metrics to generate score data from which an assessment is made to determine the articulation level of the vowels in the words spoken by the individual, allowing allow for detection, diagnosis, prediction and / or monitoring progression of the condition, disorder, or disease.

The present invention provides a control device that can detect operators who are presumed to be in a state where operating a mobile device is undesirable, such as dementia, while also minimizing inconvenience for healthy operators. [Solution] In the control device 10, the question control unit 3 displays a question on the display unit 13 to the driver operating the vehicle, and the output control unit 5 issues a warning or restricts the starting of the vehicle's engine based on the driver's answers to the questions. The question control unit 3 also controls the frequency of presenting subsequent questions based on the driver's answers.

The objective of the present invention is to provide an Alzheimer-type dementia suppressant that is safe and thus can be administered daily and utilized as a health food and by which Alzheimer-type dementia can be suppressed, and a method for producing the Alzheimer-type dementia suppressant. In addition, the objective of the present invention is also to provide a use of an aboveground part of Sesamum indicum or an extract thereof for suppressing Alzheimer-type dementia, and a method for suppressing Alzheimer-type dementia. The Alzheimer-type dementia suppressant according to the present invention is characterized in comprising an aboveground part of Sesamum indicum or an extract thereof as an active ingredient.

The present disclosure provides pharmaceutical compositions comprising a cannabinoid, and dosage forms comprising same, for oral delivery, such as sublingual or buccal delivery. The compositions of the present disclosure are substantially homogeneous and remain stable and monophasic upon storage. Also provided are methods of using the compositions for pain management and to treat various diseases and conditions, including dementia, sleep disorders, movement disorders, mental disorders, and multiple sclerosis.

Disclosed is a quinoline compound and a use thereof. A quinoline derivative of the present invention is a compound having phosphodiesterase 3A (PDE3A) inhibitory activity, has important potential therapeutic value, and is used in the treatment of cerebrovascular diseases or in dementia drugs.

The article of the present design, as shown in the reference drawings showing examples of embodiments, is a robot primarily used to assist in the care of elderly people with dementia. As shown in each drawing, the waist can move back and forth, and by leaning forward, it can get closer to the person being cared for without causing a feeling of pressure.

Dementia wayfinding sign template

The invention discloses a dementia disease identification method and system based on space-time-frequency multi-dimensional feature fusion, and belongs to the technical field of smart medical treatment. The method comprises the following steps: preprocessing an electroencephalogram signal of a target user; extracting space-time-frequency multi-dimensional features of the preprocessed electroencephalogram signals; and performing classification based on the space-time-frequency multi-dimensional features to obtain a dementia disease recognition result. According to the invention, high-precision and automatic identification can be carried out on dementia diseases such as Alzheimer disease and frontotemporal dementia.

An apparatus and a method for predicting dementia by using polyhedral drawing are disclosed. The disclosed method comprises: step (a) of acquiring a polyhedral drawing image drawn by a user; step (b) of converting the polyhedral drawing image into graph structure data having nodes and edges; step (c) of inputting the graph structure data into a graph neural network to obtain an embedding vector for the graph structure; step (d) of obtaining feature vectors for additional information including the user's age input from the user; step (e) of inputting the embedding vector and the feature vectors for the additional information into a self-attention neural network to calculate the importance of each of the vectors; and step (f) of determining whether the user has dementia through neural network calculation on the basis of a result of the importance calculated in step (e). According to the disclosed apparatus and method, it is advantageous in that the initial diagnosis accuracy of dementia can be increased by using an artificial neural network by appropriate pre-processing of a polyhedral drawing, and the initial diagnosis accuracy of dementia can be increased by integrally analyzing various types of data by using a complex artificial intelligence system.

An object of the system according to the embodiment is to allow a dementia patient to correctly and clearly recover past memories.SOLUTION: A system according to an embodiment includes smart glasses, a face recognition unit, a speech recognition unit, a generation and AI unit, and a display unit. The face recognition unit recognizes a face using a camera built in the smart glasses. The voice recognition unit recognizes voice using a microphone built in the smart glasses. The generation AI unit summarizes the memory based on the information obtained from the face recognition unit and the speech recognition unit. The display part displays the memory summarized by the generation AI part.SELECTED DRAWING: Figure 1

Dementia wayfinding sign template

Provided is a composition for maintaining, improving or ameliorating a cognitive function, the composition containing cells of Bifidobacterium adolescentis JCM 7045 strain or a treated product of the cells.

1. Name of the product in this design: Multisensory Stimulation Therapy Apron. 2. Purpose of this design: This design is specifically designed for Alzheimer's disease and dementia patients. It provides sensory stimulation through tactile, visual, and auditory interactive modules in the apron, and is suitable for emotional comfort and cognitive training scenarios. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: a 3D model. 5. This design is for a thin product, therefore the left view, right view, top view, and bottom view are omitted.

The present invention relates to compounds according to formula (I), which are prodrugs of the psychoactive compound phenethylamine or its derivatives. The prodrugs provided herein exhibit improved pharmacokinetic properties during uptake as compared to phenethylamine (or the respective phenethylamine derivative), as well as reduced side effects resulting from the metabolites thus formed. Due to the affinity of the active phenethylamine compound, inter alia, for the 5-HT2a-receptor, these prodrugs are particularly advantageous for use in therapy, e.g., in the treatment of depression, posttraumatic stress disorder (PTSD), Alzheimer's disease or dementia.

Dementia-friendly wayfinding signage

The invention relates to a novel compound as a 5-HT2A receptor inverse agonist, and a preparation method and a pharmaceutical composition thereof. The invention also relates to application of the compound or the pharmaceutical composition in preparation of drugs for treating 5-HT2A receptor related diseases, wherein the diseases comprise non-motor symptoms caused by Parkinson's disease, such as delusional disorder, hallusion, depression, anxiety, cognitive disorder and sleep disorder; dementia-related mental disorders; major depression; or negative symptoms of schizophrenia and the like.